Loading
A phase 2 trial of L19TNF in glioma & glioblastoma, run by Philogen S.p.A., active and no longer recruiting.
A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence is a phase 2 interventional study registered as NCT06336291 by Philogen S.p.A., with 90 participants enrolled, started 2024-05-22 and due to reach its primary completion in 2026-06. Interventions recorded: L19TNF and Lomustine.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Philogen S.p.A., Glioma & glioblastoma and the tag pipeline.
Shares Philogen S.p.A. and the tag pipeline.
Shares Philogen S.p.A. and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Philogen S.p.A. and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/